CTNM
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ Listed Apr 5, 2024$11.94
-1.81%
vs $12.16
Mkt Cap $446.4M
52w Low $3.69
65.3% of range
52w High $16.33
50d MA $13.03
200d MA $12.50
P/E (TTM)
-5.5x
EV/EBITDA
—
P/B
1.3x
Debt/Equity
0.0x
ROE
-23.0%
P/FCF
-6.0x
RSI (14)
33.40
ATR (14)
$0.93
Beta
1.39
50d MA
$13.03
200d MA
$12.50
Avg Volume
196.9K
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
CIK (SEC)
Phone
(858) 333-5280
10578 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | -0.50 | -0.49 | +2.0% | 13.81 | +6.5% | +0.5% | -2.4% | -1.0% | +11.7% | -7.5% | — |
| Oct 30, 2025 | AMC | -0.58 | -0.45 | +22.4% | 10.54 | +0.9% | +4.5% | -3.3% | -2.4% | +0.5% | +5.5% | — |
| Aug 5, 2025 | AMC | -0.56 | -0.62 | -10.7% | 6.00 | +3.0% | +5.5% | +6.3% | -3.9% | -0.6% | +5.0% | — |
| May 14, 2025 | AMC | -0.56 | -0.62 | -10.7% | 3.84 | +0.0% | +2.6% | -10.9% | +24.5% | -12.4% | +0.8% | — |
| Mar 6, 2025 | AMC | -0.44 | -0.56 | -27.3% | 6.44 | -0.6% | +5.1% | +9.3% | +2.3% | -0.1% | -5.6% | — |
| Nov 6, 2024 | AMC | -0.41 | -0.40 | +2.4% | 17.24 | +0.6% | +7.6% | -0.8% | +5.1% | +1.6% | -4.6% | — |
| Aug 13, 2024 | AMC | -0.35 | -0.39 | -11.4% | 16.27 | +0.6% | +6.2% | +7.6% | -7.8% | +8.5% | -5.3% | — |
| May 16, 2024 | AMC | -0.46 | -3.55 | -671.7% | 14.96 | -1.4% | +3.6% | +1.4% | +1.8% | -0.9% | +1.6% | — |
| Dec 31, 2023 | AMC | — | -0.31 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.25 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | 1.62 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.19 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Baird | Maintains | Outperform → Outperform | — | $13.81 | $14.71 | +6.5% | +0.5% | -2.4% | -1.0% | +11.7% | -7.5% |
| Jan 8 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $9.56 | $9.09 | -4.9% | -4.1% | +1.5% | -1.5% | +18.9% | +7.9% |
| Nov 24 | Baird | Maintains | Outperform → Outperform | — | $10.95 | $10.87 | -0.7% | -5.4% | +3.4% | +0.5% | +2.9% | -0.7% |
| Nov 21 | RBC Capital | Maintains | Outperform → Outperform | — | $12.22 | $10.97 | -10.2% | -10.4% | -5.4% | +3.4% | +0.5% | +2.9% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $7.38 | $7.44 | +0.8% | +9.8% | +14.8% | -4.6% | +13.2% | -1.0% |
| May 19 | Morgan Stanley | Maintains | Overweight → Overweight | — | $3.51 | $3.51 | +0.0% | +24.5% | -12.4% | +0.8% | +1.3% | -8.7% |
| May 15 | RBC Capital | Maintains | Outperform → Outperform | — | $3.84 | $3.84 | +0.0% | +2.6% | -10.9% | +24.5% | -12.4% | +0.8% |
| Mar 7 | Baird | Maintains | Outperform → Outperform | — | $6.44 | $6.40 | -0.6% | +5.1% | +9.3% | +2.3% | -0.1% | -5.6% |
| Jan 9 | RBC Capital | Maintains | Outperform → Outperform | — | — | — | — | — | — | — | — | — |
| Nov 7 | RBC Capital | Maintains | Outperform → Outperform | — | $17.24 | $17.34 | +0.6% | +7.6% | -0.8% | +5.1% | +1.6% | -4.6% |
| Aug 14 | RBC Capital | Maintains | Outperform → Outperform | — | $16.27 | $16.37 | +0.6% | +6.2% | +7.6% | -7.8% | +8.5% | -5.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Lorrain Daniel S.Off | Chief Scientific Officer | Sell | 4,170 | $13.16 | $55K | 139,372 | -5.42% | +0.35% |
| May 1, 2026 | Lorrain Daniel S.Off | Chief Scientific Officer | Sell | 300 | $13.84 | $4K | 143,542 | +7.20% | -0.68% |
| May 1, 2026 | Lorrain Daniel S.Off | Chief Scientific Officer | Sell | 3,870 | $13.06 | $51K | 143,842 | +7.20% | -0.68% |
8-K · 2.02
!! High
Contineum Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Contineum Therapeutics disclosed financial results and operational performance in a press release, providing investors with updated company metrics and performance indicators for the reported period.
May 5
8-K
Contineum Therapeutics, Inc. -- 8-K Filing
Contineum Therapeutics increased its at-the-market offering capacity by $100 million, allowing the company to sell additional common stock shares to raise capital for operations and growth.
Mar 5
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 2,734,836 | $36M | New | Mar 2026 |
| 2 | Johnson & Johnson | 1,979,173 | $26M | — | Mar 2026 |
| 3 | Franklin Resources Inc | 1,839,227 | $24M | Reduced | Mar 2026 |
| 4 | Millennium Management | 1,535,449 | $20M | Added | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,214,173 | $16M | New | Mar 2026 |
| 6 | Fmr Llc | 814,871 | $11M | — | Mar 2026 |
| 7 | Longaeva Partners L.p. | 732,088 | $10M | Added | Mar 2026 |
| 8 | Jones Hill Capital Lp | 513,053 | $7M | New | Mar 2026 |
| 9 | Susquehanna International Group, Llp | 371,636 | $5M | Added | Mar 2026 |
| 10 | Citadel Advisors Llc | 350,200 | $5M | New | Mar 2026 |
| 11 | Adar1 Capital Management, Llc | 276,661 | $4M | New | Mar 2026 |
| 12 | Silverarc Capital Management, Llc | 307,540 | $4M | Added | Dec 2025 |
| 13 | Qube Research & Technologies Ltd | 232,534 | $3M | Added | Mar 2026 |
| 14 | Ubs Group Ag | 230,409 | $3M | Added | Mar 2026 |
| 15 | Marshall Wace, Llp | 226,302 | $3M | Added | Mar 2026 |
| 16 | Morgan Stanley | 248,572 | $3M | Added | Dec 2025 |
| 17 | Ishara Investments Lp | 142,000 | $2M | New | Mar 2026 |
| 18 | Verdad Advisers, Lp | 86,032 | $1M | New | Mar 2026 |
| 19 | Point72 Asset Management | 84,891 | $1M | Reduced | Mar 2026 |
| 20 | Renaissance Technologies Llc | 69,400 | $906K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$446.4M
Enterprise Value
$73.8M
P/E (TTM)
-5.50x
Forward P/E
—
PEG Ratio
11.51x
P/B
1.27x
P/S
—
P/FCF
-5.95x
EV/EBITDA
—
Shares Out
27.7M
Financials (TTM)
Revenue
$0
Net Income
-$60.0M
EBITDA
-$68.1M
Free Cash Flow
-$55.5M
Op Cash Flow
-$55.3M
EPS Basic
$-2.17
EPS Diluted
$-2.17
EPS Forward
$-2.06
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$276.6M
Total Liab.
$15.7M
Total Equity
$261.0M
Cash
$262.9M
LT Debt
$5.9M
Book Value/Sh
$9.42
Debt/Equity
0.03x
Current Ratio
27.50
Quick Ratio
27.50
Returns & Growth
ROE
-23.0%
ROA
-21.7%
ROIC
-25.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+0.5%
Price Returns
2W
-5.1%
1M
+5.2%
3M
-12.1%
6M
+21.9%
12M
+268.6%
Technicals
52W High
$16.33
52W Low
$3.69
50d MA
$13.03
200d MA
$12.50
RSI (14)
33.40
ATR (14)
$0.93
Beta
1.39
Avg Volume
197K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$16.67
High
$22.00
Low
$14.00
Median
$14.00
Data updated apr 25, 2026 3:44am
· Source: financialmodelingprep.com